Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00633334 · ClinicalTrials.gov registry record
Development of Early Detection Signs for Gastrointestinal Cancer
A clinical trial, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 2,499
- Enrollment target
NCT00633334 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 2,499 participants.
The verdict
NCT00633334 has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 2,499 participants
- Enrollment target
Study Summary
Therapies involving the immune system have already shown great promise in early clinical trials for the treatment of renal cell carcinoma and melanoma. One of the great challenges now facing this field is to extend these findings to other cancers. Little is currently understood about the nature of the immune response to more common gastrointestinal cancers. The first goal of this proposal is to collect blood and tissue samples from patients with early or late stage gastrointestinal cancers. These samples will be evaluated to better understand the immune response to these two cancers. The second goal of this proposal is to evaluate the specimens of these patients for changes and genetic markers that correlate with the presence of cancer. The information gathered from these studies will directly enhance our ability to design, conduct and monitor novel immunotherapeutic protocols for the treatment of patients with gastrointestinal cancer.
Interventions
- OTHER Specimen bank
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,499 participants |
| Start Date | 2003-09 |
| Est. Completion | 2016-02-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00633334
The ClinicalTrials.gov registry entry for NCT00633334 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,499 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Specimen bank is the first listed.
NCT00633334 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00633334 about?
NCT00633334 is a clinical study titled "Development of Early Detection Signs for Gastrointestinal Cancer". Therapies involving the immune system have already shown great promise in early clinical trials for the treatment of renal cell carcinoma and melanoma. One of the great challenges now facing this field is to extend these findings to other cancers. Little is currently understood about the nature of t...
What is the current status of trial NCT00633334?
This trial is currently completed. The enrollment target is 2,499 participants. The study started on 2003-09. Estimated completion is 2016-02-17.
What interventions are being tested in trial NCT00633334?
The interventions under investigation include: Specimen bank (OTHER).
Who is sponsoring clinical trial NCT00633334?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.